Maze Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2023
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Net Income	-126.13	52.23	-100.42	-114.94
Depreciation & Amortization	2.61	3.3	4.09	3.82
Stock-Based Compensation	13.18	9.65	8.75	6.74
Other Adjustments	4.89	12.3	7.07	8.42
Changes in Accounts Payable	1.92	-0.2	0.4	-3.78
Changes in Accrued Expenses	3.36	3.81	-5.09	4.83
Changes in Other Operating Activities	-6.21	-5.13	-1.62	-4.29
Operating Cash Flow	-106.39	75.95	-86.83	-99.2
Capital Expenditures	-1.37	-1.15	-0.44	-1.97
Other Investing Activities	-	-	-	-1.2
Investing Cash Flow	-68.18	-1.15	-0.44	-3.17
Issuance of Common Stock	194.2	0.73	0.21	0.15
Net Common Stock Issued (Repurchased)	194.2	0.73	0.21	0.15
Issuance of Preferred Stock	-	70.79	-	-
Net Preferred Stock Issued (Repurchased)	-	70.79	-	-
Other Financing Activities	-1.34	21.32	16.18	-
Financing Cash Flow	342.01	92.85	16.39	1.73
Net Cash Flow	167.17	167.65	-70.88	-100.65
Free Cash Flow	-137.54	74.81	-87.27	-101.17
FCF Margin	-11003.44%	44.66%	-	-
Free Cash Flow Per Share	-4.62	27.40	-38.14	-50.36
Levered Free Cash Flow	-60.53	52.86	-103.08	-116.32
Unlevered Free Cash Flow	-169.28	56.95	-101.22	-112.41

Updated Sep 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q